Vertex Urged To Target Major M&A After Another Rare Disease Failure
Slip-Up Good News For Arrowhead
Executive Summary
After the failure of a second candidate for alpha-1 antitrypsin deficiency, Vertex may have to put its cash reserves to use in M&A.
You may also be interested in...
New CRISPR Therapeutics/Vertex Data Dangle The Hope Of Cure For SCD and TDT
With more data reported at ASH, Vertex and CRISPR Therapeutics added heft to the notion that functional cures are on the horizon for the inherited blood disorders sickle cell disease and beta-thalassemia. Attention is now turning to Bluebird’s marketing strategy after a filing delay.
Vertex Suffers Setback In Its Search For Post-CF Blockbusters
Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.